Astria Therapeutics/ATXS

$14.98

1.81%
-
1D1W1MYTD1YMAX

About Astria Therapeutics

Astria Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients and families affected by rare and niche allergic and immunological diseases. Its lead product candidate, STAR-0215, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Plasma kallikrein is an enzyme that cleaves high molecular weight kininogen (HMWK), to release bradykinin. It has four therapies for on-demand treatment of HAE: BERINERT (C1 esterase inhibitor (human)), FIRAZYR (icatibant injection), KALBITOR (ecallantide) and RUCONEST (C1 esterase inhibitor (recombinant)). Its long-term preventative treatment of HAE therapies: CINRYZE (C1 esterase inhibitor (human)), HAEGARDA (C1 esterase inhibitor subcutaneous (human)), TAKHZYRO (lanadelumab-flyo) and ORLADEYO (berotralstat).

Ticker

ATXS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jill Milne

Employees

42

Headquarters

Boston, United States

ATXS Metrics

BasicAdvanced
$818.9M
Market cap
-
P/E ratio
-$2.19
EPS
0.70
Beta
-
Dividend rate

What the Analysts think about ATXS

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
39.25% upside
High $33.00
Low $17.00
$14.98
Current price
$20.86
Average price target

ATXS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-17.7M
41.6%
Profit margin
0%
-

ATXS Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 29.63%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.72
-$0.40
-$0.45
-$0.63
-
Expected
-$0.71
-$0.55
-$0.49
-$0.49
-$0.78
Surprise
1.17%
-27.51%
-7.63%
29.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Astria Therapeutics stock

Buy or sell Astria Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing